Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGENUS INCAGEN · Entity 5774 | Chief Legal Officer and GC | June 20, 2018 | June 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGENUS INC
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options, right to buySEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2028-03-02 | Direct | 173,150 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 173,150 · Balance 173,150 F1: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 58,600 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 81,939 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-15 · Disposition to issuer · Disposed 22,425 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.06 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-15 · Disposition to issuer · Disposed 41,800 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 8,550 | $11.50 | $98,325.00 |
DisclosureSEC source: 0001562180-20-001122 · primarydocument.xml · nonDerivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 18:22 UTC Amendment | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,550 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-001187 · primarydocument.xml · derivative · entry 8 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,539 Underlying: Common Stock · 8,550 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest as to 25% of the shares underlying the option on July 16, 2019, with the remainder vesting in equal quarterly installments through July 16, 2022, subject to continued service. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 18:22 UTC Amendment | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 8,550 | $35.03 | $299,506.50 |
DisclosureSEC source: 0001562180-20-001187 · primarydocument.xml · nonDerivative · entry 5 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 18:22 UTC Amendment | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 8,550 | $11.50 | $98,325.00 |
DisclosureSEC source: 0001562180-20-001187 · primarydocument.xml · nonDerivative · entry 4 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,096 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-001122 · primarydocument.xml · derivative · entry 5 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,239 Underlying: Common Stock · 14,096 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest as to 25% of the shares underlying the option on July 16, 2019, with the remainder vesting in equal quarterly installments through July 16, 2022, subject to continued service. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 14,096 | $33.51 | $472,356.96 |
DisclosureSEC source: 0001562180-20-001122 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades at prices ranging from $32.37 to $35.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:36 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 14,096 | $11.50 | $162,104.00 |
DisclosureSEC source: 0001562180-20-001122 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 18:22 UTC Amendment | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,246 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-001187 · primarydocument.xml · derivative · entry 7 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,089 Underlying: Common Stock · 12,246 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest as to 25% of the shares underlying the option on July 16, 2019, with the remainder vesting in equal quarterly installments through July 16, 2022, subject to continued service. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 18:22 UTC Amendment | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 1,850 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001562180-20-001187 · primarydocument.xml · derivative · entry 6 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,050 Underlying: Common Stock · 1,850 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on March 7, 2019, and the shares underlying the option vest in equal quarterly installments through March 7, 2023, subject to continued service. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 18:22 UTC Amendment | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 14,096 | $33.51 | $472,356.96 |
DisclosureSEC source: 0001562180-20-001187 · primarydocument.xml · nonDerivative · entry 3 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.37 to $35.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 18:22 UTC Amendment | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 12,246 | $11.50 | $140,829.00 |
DisclosureSEC source: 0001562180-20-001187 · primarydocument.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 18:22 UTC Amendment | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,850 | $8.76 | $16,206.00 |
DisclosureSEC source: 0001562180-20-001187 · primarydocument.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 16:51 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 29,900 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0000899243-19-006922 · doc4.xml · derivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,900 Underlying: Common Stock · 29,900 shares Expires 2029-03-06 F1 · derivative.exercise_date: This option was granted on March 7, 2019, and the shares underlying the option vest in equal quarterly installments through March 7, 2023, subject to continued service. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 17:42 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 145,335 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0000899243-18-020284 · doc4.xml · derivative · entry 1 Valentine Karen · CIK 0001437152 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,335 Underlying: Common Stock · 145,335 shares Expires 2028-07-18 F1 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest as to 25% of the shares underlying the option on July 16, 2019, with the remainder vesting in equal quarterly installments through July 16, 2022, subject to continued service. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 15:16 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Options, right to buy · Derivative | 173,150 | $5.65 Strike: $5.65 | $978,297.50 |
DisclosureSEC source: 0001288123-18-000007 · primary_doc.xml · derivative · entry 1 Valentine Karen · CIK 0001437152 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,150 Underlying: Common Stock · 173,150 shares Expires 2028-03-02 F1 · derivative.exercise_date: Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, and vests over three years with one-third of the award vesting on March 2, 2019 and the balance vesting in equal quarterly installments thereafter. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:14 UTC | AGENUS INC AGEN · Entity 5774 | SaleCommon Stock | 8,358 | $3.46 | $28,921.19 |
DisclosureSEC source: 0001288123-17-000040 · primary_doc.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,521 F2 · shares: Represents sales of shares sold solely to cover Federal , state and local tax on withholding requirements on the restricted shares settled and were sold at prices ranging between $3.495 and $3.44 per share. F2 · price: Represents sales of shares sold solely to cover Federal , state and local tax on withholding requirements on the restricted shares settled and were sold at prices ranging between $3.495 and $3.44 per share. Read SEC document |
| October 09, 2017 Filed Dec 14, 2017 21:14 UTC | AGENUS INC AGEN · Entity 5774 | GrantCommon Stock | 24,824 | $3.59 | $89,118.16 |
DisclosureSEC source: 0001288123-17-000040 · primary_doc.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,879 F1 · kind: Represents settlement of restricted shares awarded on July 1, 2015. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:13 UTC | AGENUS INC AGEN · Entity 5774 | Disposition to issuerCommon Stock | 8,055 | $3.39 | $27,306.45 |
DisclosureSEC source: 0001288123-17-000022 · primary_doc.xml · nonDerivative · entry 2 Valentine Karen · CIK 0001437152 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,055 F2 · kind: Represents exclusively, shares withheld by Agenus Inc. in respect of payment of the withholding tax liability upon the vesting of the restricted shares. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:13 UTC | AGENUS INC AGEN · Entity 5774 | GrantCommon Stock | 24,822 | $3.39 | $84,146.58 |
DisclosureSEC source: 0001288123-17-000022 · primary_doc.xml · nonDerivative · entry 1 Valentine Karen · CIK 0001437152 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,110 F1 · kind: Represents settlement of vested restricted shares granted on July 1, 2015. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:31 UTC | AGENUS INC agen · Entity 5774 | GrantStock Option, Right to Buy · Derivative | 162,500 | $3.77 Strike: $3.77 | $612,625.00 |
DisclosureSEC source: 0001288123-17-000010 · primary_doc.xml · derivative · entry 1 Valentine Karen · CIK 0001437152 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2027-03-31 F1 · derivative.exercise_date: Options vest one-third on the one-year anniversary of the grant date with the remainder vesting in equal quarterly installments provided the executive maintains a service relationship with the Company through each vesting date. Read SEC document |
| September 16, 2016 Filed Sep 20, 2016 20:05 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option, right to buy · Derivative | 2,083 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0000899243-16-029402 · doc4.xml · derivative · entry 1 Valentine Karen · CIK 0001437152 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,083 Underlying: Common Stock · 2,083 shares Expires 2026-09-16 F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Inventive Plan, and vests in one installment on the one-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.